Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Issues Guidance on COVID-19 Vaccines’ Immunogenicity Assessment for Non-Placebo-Controlled Trials
October 25, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- MHLW Proposes Further Measures to Promote Generics in Basic Plan for FY2022 Reimbursement Reform
October 25, 2021
- MHLW Panel OKs 81 More COVID-19 Vaccine Health Damage Claims
October 25, 2021
- Tecentriq under PMDA Safety Review for Cholangitis Sclerosing
October 25, 2021
- Herceptin’s Salivary Cancer Use Up for PAFSC Review on Nov. 4; Label Expansions for I/O Drugs, Lorbrena on Agenda Too
October 22, 2021
- Chuikyo Discusses Spillover Rules in Market Expansion Re-Pricing, PMP Criteria towards FY2022 Reform
October 21, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
- Japan to Boost Budgets for Vaccine Development and Supply: Govt Official
October 19, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
- Discussions on Health Crisis Management Agency Comes after COVID-19 Master Plan: Minister
October 18, 2021
- Japan Govt Unveils Outline of COVID-19 Responses, Eyes Oral Drug Rollout by Year-End
October 18, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- COVID-19 Vaccine Label Revised to Warn of Myocarditis Risk in Young Men
October 18, 2021
- MHLW’s Unapproved Drug Council Determines High Needs for 7 Additional Indications for Fertility Treatments
October 14, 2021
- Drug Pricing Rules to Be Applied to Takeda’s Cell Therapy Alofisel: Chuikyo
October 14, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- Label Revisions Ordered for Ivermectin to Add Disturbed Consciousness to ADR List
October 13, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…